Ophthalmologic findings in hepatitis C patients treated with pegylated interferon α-2b and ribavirin

被引:2
|
作者
De Novelli, Fernando Jose
Przysiezny, Andre
Rosa, Evandro Luis
Liermann Garcia, Raquel Francine
Nobrega, Mario Junqueira
机构
[1] Hepatol Clin Sao Jose Reg Hosp, Sao Jose, SC, Brazil
[2] Sadalla Amin Ghanem Eye Hosp, Vitreoretinal Dept, Joinville, SC, Brazil
关键词
Antiviral agents/adverse effects; Hepatitis C; chronic/drug therapy; Interferon-alpha/adverse effects; Retinal diseases/chemically induced; Ribavirin/adverse effects; CHRONIC ACTIVE HEPATITIS; CHRONIC VIRAL-HEPATITIS; INDUCED RETINOPATHY; RETINAL COMPLICATIONS; VIRUS-INFECTION; ALPHA THERAPY; HYPERTENSION; ALFA;
D O I
10.5935/0004-2749.20140045
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To identify the effect of pegylated interferon alpha-2b and ribavirin treatment in the ocular fundus examination, visual acuity, and visual field. Methods: Prospective observational study was performed at the Hepatology Clinic of Sao Jose Regional Hospital and at the Vitreoretinal Department at the Sadalla Amin Ghanem Eye Hospital in patients with chronic hepatitis C before and during treatment with pegylated interferon alpha-2b together with ribavirin. Results: Six (37.5%) of 16 patients developed retinopathy during the treatment, two of which (12.5%) presented retinal hemorrhage, and four patients (6 eyes) presented cotton-wool spots (25%) that regressed during the treatment. One patient (6.25%) presented transient decrease in visual acuity during the treatment and recovered spontaneously without specific therapy. Conclusion: Recommended treatment methods for hepatitis C may cause transient retinopathy, commonly without any damage to visual function in most patients. Although ocular involvement is rare, follow-up with an ophthalmologist is recommended during the course of the hepatitis C medication.
引用
收藏
页码:178 / 181
页数:4
相关论文
共 50 条
  • [1] Pegylated Interferon α-2b, Ribavirin and Amantadine for Chronic Hepatitis C
    Zobair M. Younossi
    Arthur C. McCullough
    David S. Barnes
    Anthony Post
    Janus P. Ong
    Robert O’shea
    Lisa M. Martin
    Diane Bringman
    Denise Farmer
    Gavin Levinthal
    Kevin D. Mullen
    William D. Carey
    Anthony S. Tavill
    Roy Ferguson
    Terry Gramlich
    Digestive Diseases and Sciences, 2005, 50 : 970 - 975
  • [2] Pegylated interferon α-2b, ribavirin and amantadine for chronic hepatitis C
    Younossi, ZM
    McCullough, A
    Barnes, D
    Post, A
    Ong, J
    O'Shea, R
    Martin, LM
    Bringman, D
    Farmer, D
    Levinthal, G
    Mullen, KD
    Carey, WD
    Tavill, AS
    Ferguson, R
    Gramlich, T
    DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (05) : 970 - 975
  • [3] Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
    Kainuma, Mosaburo
    Furusyo, Norihiro
    Kajiwara, Eiji
    Takahashi, Kazuhiro
    Nomura, Hideyuki
    Tanabe, Yuichi
    Satoh, Takeaki
    Maruyama, Toshihiro
    Nakamuta, Makoto
    Kotoh, Kazuhiro
    Azuma, Koichi
    Shimono, Junya
    Shimoda, Shinji
    Hayashi, Jun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (35) : 4400 - 4409
  • [4] Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
    Mosaburo Kainuma
    Norihiro Furusyo
    Eiji Kajiwara
    Kazuhiro Takahashi
    Hideyuki Nomura
    Yuichi Tanabe
    Takeaki Satoh
    Toshihiro Maruyama
    Makoto Nakamuta
    Kazuhiro Kotoh
    Koichi Azuma
    Junya Shimono
    Shinji Shimoda
    Jun Hayashi
    World Journal of Gastroenterology, 2010, 16 (35) : 4400 - 4409
  • [5] Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
    Pennisi, Manuela
    Bertino, Gaetano
    Gagliano, Caterina
    Malaguarnera, Michele
    Bella, Rita
    Borzi, Antonio Maria
    Madeddu, Roberto
    Drago, Filippo
    Malaguarnera, Giulia
    NUTRIENTS, 2017, 9 (08):
  • [6] Catatonia Associated with Pegylated Interferon-α 2b and Ribavirin for Hepatitis C
    Quinn, Davin
    Kuchler, Elizabeth
    Deming, Paulina
    Arora, Sanjeev
    PSYCHOSOMATICS, 2012, 53 (04) : 400 - 401
  • [7] Response to pegylated interferon α-2b and ribavirin in children with chronic hepatitis C
    Baker, Robert D.
    Dee, Deborah
    Baker, Susan S.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (01) : 111 - 114
  • [8] IMPACT OF THE VIRAL KINETICS OF CHRONIC HEPATITIS C PATIENTS TREATED WITH TELAPREVIR IN COMBINATION WITH PEGYLATED INTERFERON α2b AND RIBAVIRIN
    Ogawa, E.
    Furusyo, N.
    Nakamuta, M.
    Kajiwara, E.
    Nomura, H.
    Dohmen, K.
    Takahashi, K.
    Satoh, T.
    Azuma, K.
    Kawano, A.
    Tanabe, Y.
    Kotoh, K.
    Shimoda, S.
    Hayashi, J.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S365 - S365
  • [9] Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous
    Lawitz, EJ
    Bala, NS
    Becker, S
    Brown, G
    Davis, M
    Dhar, R
    Ganeshappa, KP
    Gordon, S
    Holtzmuller, K
    Jeffries, M
    Li, JJ
    Monsour, H
    Nader, P
    Rosenfield, T
    Tolman, K
    Kadakia, S
    GASTROENTEROLOGY, 2003, 124 (04) : A783 - A784
  • [10] Pegylated interferon α2a plus ribavirin versus pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
    Berenguer, J.
    Gonzalez-Garcia, J.
    Lopez-Aldeguer, J.
    Von-Wichmann, M. A.
    Quereda, C.
    Hernando, A.
    Sanz, J.
    Tural, C.
    Ortega, E.
    Mallolas, J.
    Santos, I.
    Miralles, P.
    Montes, M. L.
    Bellon, J. M.
    Esteban, H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (06) : 1256 - 1263